Insight Molecular Diagnostics Inc. quarterly report, Q1 FY2017

Business context and reporting period

The supplied filing is OncoCyte Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2017; this differs from the request metadata naming Insight Molecular Diagnostics Inc. OncoCyte is developing molecular cancer diagnostics, with programs focused on lung, bladder, and breast cancer. It reported no revenue in either comparable quarter.

On February 17, 2017, BioTime’s ownership fell below 50% following warrant exercises, and BioTime deconsolidated OncoCyte. BioTime remained an affiliate with significant influence and continued providing services.

Financial results and position

Revenue-based margins are not meaningful because the company had no revenue. At March 31, 2017, cash and cash equivalents were $11.352 million, BioTime shares held as available-for-sale securities were valued at $1.649 million, and working capital was approximately $8.9 million. Total assets were $15.174 million and total liabilities were $6.401 million. The bank loan had $2.0 million principal outstanding; its balance sheet carrying amount was approximately $1.922 million, net of issuance costs. Capital lease liabilities totaled $465,000. Accumulated deficit was $40.006 million.

Material changes versus the prior comparable period

• Operating expenses rose 54.6%. Research and development increased 8.6% to $1.834 million; general and administrative increased 101.3% to $2.043 million; and sales and marketing increased 187.3% to $655,000.
• Net loss grew to $4.704 million from $2.928 million. General and administrative expense included a $1.1 million noncash charge for warrants issued to induce warrant exercises.
• Research and development spending shifted across programs: lung cancer spending decreased to $644,000 from $805,000; spending on the diagnostics laboratory increased to $240,000 from $35,000.
• Cash increased by $1.178 million during the quarter, versus a $2.140 million decrease in Q1 2016, supported by $2.031 million of warrant exercise proceeds and a $2.0 million bank borrowing.

Outlook, risks, and unusual items

• Management expects continued operating losses and negative cash flows while investing in research and development. It stated that cash, securities, and working capital were sufficient for current operations for at least 12 months from the financial-statement issuance date, but additional capital would be needed if it proceeded to commercialize the lung test during that period and for future development and launches.
• Commercialization depends in part on successful CLIA and validity studies for the lung cancer test. The filing gives no revenue or earnings guidance and does not specify a launch date.
• OncoCyte borrowed $2.0 million from Silicon Valley Bank in March 2017. The secured loan bears floating interest (4.75% at March 31), requires interest-only payments through October 2017, then monthly principal and interest, and matures in April 2020. A potential additional $3.0 million tranche is conditional on raising at least $20 million in equity, launching the initial lung test, and meeting other conditions. Loan covenants and default provisions include material-adverse-change and delisting triggers.
• Proceeds from sales of BioTime shares may only be used to repay amounts owed to BioTime and affiliates. The company sold 141,844 shares for $502,000 and recorded a $155,000 loss after BioTime deconsolidation.
• OncoCyte owed BioTime and affiliates $2.610 million at quarter-end. Shared facilities and services charges continue under an agreement; management allocates costs based on usage and other drivers.
• The filing reports no material litigation, no off-balance-sheet arrangements, and no material changes in market risk. It identifies no assurance of future financing, potential shareholder dilution from equity issuance, and the risk that insufficient financing could force delays or reductions in planned operations.
• A subsequent equipment lease entered on April 13, 2017 required payments of $9,462 per month for 36 months and exhausted the remaining availability under the equipment lease line.

Important facts for investors to verify

• Confirm the issuer identity: the filing is for OncoCyte Corporation, not the company named in the request metadata.
• Track lung-test study outcomes, regulatory and laboratory readiness, and any announced commercialization timing.
• Assess cash burn and financing needs against the company’s stated 12-month liquidity view, including the conditional requirements for the additional bank tranche.
• Review dilution exposure from outstanding warrants and options, and the terms and collateral provisions of the bank loan.
• Monitor related-party charges and balances with BioTime, including the permitted use of proceeds from BioTime share sales.